Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance

Molecular Neurobiology

Volumn 52, Issue 1, 2015, Pages 115-119

  Liu, Yu Hui ^a   Xiang, Yang ^a   Wang, Ye Ran ^a   Jiao, Shu Sheng ^a   Wang, Qing Hua ^a   Bu, Xian Le ^a   Zhu, Chi ^a   Yao, Xiu Qing ^a   Giunta, Brian ^b   Tan, Jun ^b   Zhou, Hua Dong ^a   Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer s disease; A ; Chronic kidney disease; Peripheral clearance

Indexed keywords

AMINOTRANSFERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLESTEROL; CREATININE; CYSTATIN C; GLUCOSE; THYROXINE; UREA; URIC ACID;

ADULT; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CLEARANCE; MALE; MIDDLE AGED; NEUROPROTECTION; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RESIDUAL ESTIMATED GLOMERULUS FILTRATION RATE; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; DEMOGRAPHY; KIDNEY; METABOLISM; PATHOPHYSIOLOGY;

AMYLOID BETA-PEPTIDES; DEMOGRAPHY; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84937978484     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8854-y     Document Type: Article

References (20)

1. Coresh J et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047
2. James BD et al (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82(12):1045–1050
3. Lemere CA et al (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14(1):10–18
4. Liu YH, et al (2014) Clearance of Amyloid-Beta in Alzheimer's Disease: Shifting the Action Site from Center to Periphery. Mol Neurobiol
5. Wang YJ (2014) Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10(4):188–189
6. Liu YH et al (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8(8):465–469
7. Miwa K et al (2014) Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 82(12):1051–1057
8. Li J et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76(17):1485–1491
9. Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
10. Hoek FJ et al (2007) Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 22(6):1633–1638
11. Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11(19–20):931–938
12. Ghiso J et al (1997) Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett 408(1):105–108
13. Arvanitakis Z et al (2002) Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 16(3):187–190
14. Delaney MP et al (2008) Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 51(2):278–284
15. Helmer C et al (2011) Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 77(23):2043–2051
16. Bradshaw EM et al (2013) CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16(7):848–850
17. Sehgal N et al (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109(9):3510–3515
18. Liu Y et al (2010) Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 45(2):101–107
19. Henderson SJ et al (2014) Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain 137(Pt 2):553–564
20. Walker JR et al (2013) Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J Neurosci 33(6):2457–2464